Cost-effectiveness analysis: Can we reduce variability in costing methods?

International Journal of Technology Assessment in Health Care

Volumn 19, Issue 2, 2003, Pages 407-420

  Adam, Taghreed ^a   Evans, David B ^a   Koopmanschap, Marc A ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Costs and cost analysis; Economic evaluation; Generalizability; Methods

Indexed keywords

COSTS; ECONOMICS; PUBLIC POLICY;

ECONOMIC APPRAISALS;

HEALTH CARE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; PRACTICE GUIDELINE; TECHNIQUE;

EID: 0037678424     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462303000369     Document Type: Article

References (59)

1. Alban A, Gyldmark M, Pedersen AV, Sogaard J. The Danish approach to standards for economic evaluation methodologies. Pharmacoeconomics. 1997;12:627-636.
2. Asian Development Bank. Guidelines for the economic analysis of projects. Manila: Asian Development Bank; 1997.
3. Barnum H, Kutzin J. Public hospitals in developing countries. Resource use, cost, financing. Baltimore: The Johns Hopkins University Press for the World Bank; 1993.
4. Bratt JH, Foreit J, Chen P-L, et al. A comparison of four approaches for measuring clinician time use. Health Policy Plan. 1999;14:374-381.
5. Brouwer WB, van Exel NJ, Koopmanschap MA, Rutten FF. The valuation of informal care in economic appraisal. A consideration of individual choice and societal costs of time. Int J Technol Assess Health Care. 1999;15:147-160.
6. Brouwer WBF, Koopmanschap MA, Rutten FFH. Patient and informal caregiver time in cost-effectiveness analysis. Int J Technol Assess Health Care. 1998;14:505-513.
7. Brown J. Economic evaluation of cancer treatments: A review of the methods. Clin Oncol (R Coll Radiol). 1999;11:78-83.
8. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals. Ottawa: CCOHTA; 1997.
9. Cohen DJ, Breall JA, Ho KK, et al. Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J Am Coll Cardiol. 1993;22:1052-1059.
10. Commonwealth of Australia. Guidelines for pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: Including economic analyses. Canberra: Department of Health and Community Services; 1995.
11. Creese A, Parker D. Cost analysis in primary health care: A training manual for programme managers. Geneva: World Health Organization; 1994.
12. Dinwiddy C, Teal F. Principles of cost-benefit analysis for developing countries. Cambridge: Cambridge University Press; 1996.
13. Drummond M, Brandt A, Luce B, Rovira J. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol. Assess. Health Care. 1993;9:26-36.
14. Drummond MF, O'Brien B, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programs. Oxford: Oxford University Press; 1997.
15. Evers SM, Van Wijk AS, Ament AJ. Economic evaluation of mental health care interventions. A review. Health Econ. 1997;6:161-177.
16. Fryatt RJ. Review of published cost-effectiveness studies on tuberculosis treatment programmes. Int J Tuberc Lung Dis. 1997;1:101-109.
17. Garattini L, Giuliani G, Pagano E. A model for calculating costs of hospital wards: An Italian experience. J Manag Med. 1999;13:71-82.
18. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1-31.
19. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
20. Health-Care Economics Consensus Group. Health economic guidelines: The German perspective revisited. Pharmacoeconomics Outcomes News. 1996;56:4-6.
21. Holloway RG, Benesch CG, Rahilly CR, Courtright CE. A systematic review of cost-effectiveness research of stroke evaluation and treatment. Stroke. 1999;30:1340-1349.
22. Hutubessy RCW, Bendib LM, Evans DB. Critical issues in the economic evaluation of interventions against communicable diseases. Acta Trop. 2001;78:191-206.
23. Jacobs P, Bachynsky J. Costing methods in the Canadian literature on the economic evaluation of health care. Int J Technol Assess Health Care. 1996;12:721-734.
24. Jacobs P, Bachynsky J, Baladi J-F. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics. 1995;8:182-189.
25. Johannesson M. On aggregating QALYs: A comment on Dolan [see comments]. J Health Econ. 1999;18:381-386.
26. Johannesson M, Jonsson B. Cost-effectiveness analysis of hypertension treatment: A review of methodological issues. Health Policy. 1991;19:55-77.
27. Johannesson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ. 1998;7:1-7.
28. Johnston K, Buxton MJ, Jones DR, Fitzpatrick R. Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess. 1999;3:1-76.
29. Koopmanschap MA, Brouwer WBF. Controversial costs in guidelines. In: Pinto JL, Lopez-Casasnovas G, Ortun V, eds. Economic evaluation. From theory to practice. New York: Springer; 2001:129-143.
30. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. Reply to Johannesson's and Karlsson's comment. J Health Econ. 1997;16:257-259.
31. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171-189.
32. Kortt MA, Bootman JL. The economics of benign prostatic hyperplasia treatment: A literature review. Clin Ther. 1996;18:1227-1241.
33. Kotsopoulos IA, Evers SM, Ament AJ, de Krom MC. Estimating the costs of epilepsy: An international comparison of epilepsy cost studies. Epilepsia. 2001;42:634-640.
34. Kumaranayake L, Pepperall J, Goodman H, Mills A, Walker D. Costing guidelines for HIV/AIDS prevention strategies. A companion volume to: Cost analysis in primary health care: A training manual for programme managers. London: Health Economics and Financing Programme, London School of Hygiene and Tropical Medicine; 2000.
35. Langley PC. The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics. 1996;9:341-352.
36. Mair FS, Haycox A, May C, Williams T. A review of telemedicine cost-effectiveness studies. J Telemed Telecare. 2000;6(Suppl 1):S38-S40.
37. Medicare Services Advisory Committee. Funding for new medical technologies and procedures: Application and assessment guidelines. Canberra: Department of Health and Aged Care; 2000.
38. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16:33-64.
39. Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Ontario: Ministry of Health; 1994.
40. Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. Clin Ther. 1998;20:1194-1202.
41. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9:235-251.
42. Newell M-L, Dabis F, Tolley K, Whynes D. Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. AIDS. 1998;12:1571-1580.
43. Oostenbrink JB, Koopmanschap MA, Rutten F. The Dutch manual for costing in economic evaluations. Pharmacoeconomics. In press.
44. Petrou S, Henderson J, Roberts T, Martin MA. Recent economic evaluations of antenatal screening: A systematic review and critique. J Med Screen. 2000;7:59-73.
45. Phillips M, Mills A, Dye C. Guidelines for cost-effectiveness analysis of vector control. Geneva: World Health Organization; 1993.
46. Salah H, Walsh J, Kumar N. Cost analysis and efficiency indicators for health care: Report number 5 summary output for 19 primary health care facilities in Alexandria, Bani Suef and Suez 1993-1994. US Department of Planning, Ministry of Health and Population, Data for Decision Making, Harvard School of Public Health, University of California, Berkeley, School of Public Health; 1997.
47. Schrappe M, Lauterbach K. Systematic review on the cost-effectiveness of public health interventions for HIV prevention in industrialized countries. AIDS. 1998;12(Suppl A):S231-S238.
48. Shepard DS, Hodgkin D, Anthony YE. Analysis of hospital costs: A manual for managers. Geneva: World Health Organization; 2000.
49. Stewart A, Schmier JK, Luce BR. A survey of standards and guidelines for cost-effectiveness analysis in health care. Am Heart J. 1999;137:S53-S61.
50. Stone PW, Chapman RH, Sandberg EA, Liljas B, Neumann PJ. Measuring costs in cost-utility analyses. Variations in the literaturet. Int J Technol. Assess Health Care. 2000;16:111-124.
51. Torrance GW, Blaker D. Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. Pharmacoeconomics. 1996;9:535-559.
52. Walker D. How to do (or not to do) … Cost and cost-effectiveness guidelines: Which ones to use? Health Policy Plan. 2001;16:113-121.
53. Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: A critical review of the published literature. Health Econ. 2000;9:681-698.
54. Walker D, Fox-Rushby J. Economic evaluation of parasitic diseases: A critique of the internal and external validity of published studies. Trop Med Int Health. 2000;5:237-249.
55. Weinstein MC, Manning WG, Jr. Theoretical issues in cost-effectiveness analysis. J Health Econ. 1997;16:121-128. Editorial.
56. World Health Organization/Expanded Programme on Immunization. Expanded programme on immunization: Costing guidelines. Geneva: World Health Organization; 1997.
57. World Health Organization. Estimating costs for cost-effectiveness analysis: Guidelines for managers of diarrhoeal diseases control programmes. Geneva: World Health Organization; 1988.
58. World Health Organization. Safe blood and blood products: Costing blood transfusion services. Geneva: World Health Organization; 1998.
59. World Health Organization. Generic protocols for cost and cost-effectiveness analysis of TB diagnosis and treatment services. Geneva: World Health Organization; 1999.